BCL2在晚期前列腺癌中的表达及其与去势耐药性的关系

R.F. Velázquez-Macías , F.E. De La Torre-Rendón , G. Ramos-Rodríguez , C.A. Calzada-Mendoza , R.M. Coral-Vázquez
{"title":"BCL2在晚期前列腺癌中的表达及其与去势耐药性的关系","authors":"R.F. Velázquez-Macías ,&nbsp;F.E. De La Torre-Rendón ,&nbsp;G. Ramos-Rodríguez ,&nbsp;C.A. Calzada-Mendoza ,&nbsp;R.M. Coral-Vázquez","doi":"10.1016/j.uromx.2016.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and aims</h3><p>The study of the anti-apoptotic protein, Bcl2, in localized prostate cancer has not been carried out in advanced stages of the disease. Therefore the aim of our study was to evaluate Bcl2 expression in advanced prostate cancer and identify its association with age, body weight, height, body mass index, prostate-specific antigen, testosterone, Gleason score, bone metastasis, disease duration, and time until the appearance of hormone resistance.</p></div><div><h3>Material and method</h3><p>A comparative study was conducted on 19 patients with castration-resistant prostate cancer (CRPC) and 19 patients with hormone-sensitive prostate cancer (HSPC). Bcl2 was identified in a blinded manner through immunohistochemistry in prostate biopsies.</p></div><div><h3>Results</h3><p>Prostate-specific antigen was higher in patients with CRPC and disease duration was 39.71 months for CRPC and 23.89 months for HSPC. Resistance appeared at 30.05 months. There were no significant differences in relation to the other variables. Bcl2 was identified in 63.16% of the patients with CRPC and in 84.21% of those with HSPC, odds ratio 0.32, 95% CI: 0.07-1.45. There was mild staining intensity in 47.37% of the CRPC cases and moderate staining in 15.79%. Staining was mild in 57.89% of the HSPC patients and moderate in 26.32%. The differences were not significant. Correlation analysis showed a negative correlation trend between Bcl2 and body weight and a positive trend between Bcl2 and disease duration, with no statistical significance.</p></div><div><h3>Conclusion</h3><p>Bcl2 was identified in advanced prostate cancer and showed a trend toward greater expression in hormone-sensitive cancer. There was no correlation between Bcl2 and the clinical variables analyzed. However, there was a negative correlation between Bcl2 stain intensity and body weight and a positive trend between Bcl2 and disease duration.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2016.07.001","citationCount":"0","resultStr":"{\"title\":\"Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración\",\"authors\":\"R.F. Velázquez-Macías ,&nbsp;F.E. De La Torre-Rendón ,&nbsp;G. Ramos-Rodríguez ,&nbsp;C.A. Calzada-Mendoza ,&nbsp;R.M. Coral-Vázquez\",\"doi\":\"10.1016/j.uromx.2016.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and aims</h3><p>The study of the anti-apoptotic protein, Bcl2, in localized prostate cancer has not been carried out in advanced stages of the disease. Therefore the aim of our study was to evaluate Bcl2 expression in advanced prostate cancer and identify its association with age, body weight, height, body mass index, prostate-specific antigen, testosterone, Gleason score, bone metastasis, disease duration, and time until the appearance of hormone resistance.</p></div><div><h3>Material and method</h3><p>A comparative study was conducted on 19 patients with castration-resistant prostate cancer (CRPC) and 19 patients with hormone-sensitive prostate cancer (HSPC). Bcl2 was identified in a blinded manner through immunohistochemistry in prostate biopsies.</p></div><div><h3>Results</h3><p>Prostate-specific antigen was higher in patients with CRPC and disease duration was 39.71 months for CRPC and 23.89 months for HSPC. Resistance appeared at 30.05 months. There were no significant differences in relation to the other variables. Bcl2 was identified in 63.16% of the patients with CRPC and in 84.21% of those with HSPC, odds ratio 0.32, 95% CI: 0.07-1.45. There was mild staining intensity in 47.37% of the CRPC cases and moderate staining in 15.79%. Staining was mild in 57.89% of the HSPC patients and moderate in 26.32%. The differences were not significant. Correlation analysis showed a negative correlation trend between Bcl2 and body weight and a positive trend between Bcl2 and disease duration, with no statistical significance.</p></div><div><h3>Conclusion</h3><p>Bcl2 was identified in advanced prostate cancer and showed a trend toward greater expression in hormone-sensitive cancer. There was no correlation between Bcl2 and the clinical variables analyzed. However, there was a negative correlation between Bcl2 stain intensity and body weight and a positive trend between Bcl2 and disease duration.</p></div>\",\"PeriodicalId\":34909,\"journal\":{\"name\":\"Revista mexicana de urologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.uromx.2016.07.001\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista mexicana de urologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2007408516300453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408516300453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

引言和目的对癌症晚期局限性前列腺癌中抗凋亡蛋白Bcl2的研究尚未进行。因此,我们研究的目的是评估Bcl2在晚期癌症中的表达,并确定其与年龄、体重、身高、体重指数、前列腺特异性抗原、睾酮、Gleason评分、骨转移、疾病持续时间和出现激素抵抗的时间的关系。材料与方法对19例去势抵抗性前列腺癌症(CRPC)和19例激素敏感性前列腺癌症(HSPC)患者进行比较研究。Bcl2在前列腺活检中通过免疫组织化学以盲法鉴定。结果CRPC患者前列腺特异性抗原含量较高,CRPC患者病程39.71个月,HSPC患者病程23.89个月。30.05个月出现耐药性。与其他变量相比,没有显著差异。Bcl2在63.16%的CRPC患者和84.21%的HSPC患者中被鉴定,比值比为0.32,95%CI:0.07-1.45。CRPC中47.37%为轻度,15.79%为中度,HSPC中57.89%为轻度,26.32%为中度,差异无统计学意义。相关分析显示Bcl2与体重呈负相关,与病程呈正相关,无统计学意义。结论Bcl2在晚期癌症中有表达,在激素敏感性癌症中有表达增加的趋势。Bcl2与分析的临床变量之间没有相关性。然而,Bcl2染色强度与体重呈负相关,Bcl2与疾病持续时间呈正相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración

Introduction and aims

The study of the anti-apoptotic protein, Bcl2, in localized prostate cancer has not been carried out in advanced stages of the disease. Therefore the aim of our study was to evaluate Bcl2 expression in advanced prostate cancer and identify its association with age, body weight, height, body mass index, prostate-specific antigen, testosterone, Gleason score, bone metastasis, disease duration, and time until the appearance of hormone resistance.

Material and method

A comparative study was conducted on 19 patients with castration-resistant prostate cancer (CRPC) and 19 patients with hormone-sensitive prostate cancer (HSPC). Bcl2 was identified in a blinded manner through immunohistochemistry in prostate biopsies.

Results

Prostate-specific antigen was higher in patients with CRPC and disease duration was 39.71 months for CRPC and 23.89 months for HSPC. Resistance appeared at 30.05 months. There were no significant differences in relation to the other variables. Bcl2 was identified in 63.16% of the patients with CRPC and in 84.21% of those with HSPC, odds ratio 0.32, 95% CI: 0.07-1.45. There was mild staining intensity in 47.37% of the CRPC cases and moderate staining in 15.79%. Staining was mild in 57.89% of the HSPC patients and moderate in 26.32%. The differences were not significant. Correlation analysis showed a negative correlation trend between Bcl2 and body weight and a positive trend between Bcl2 and disease duration, with no statistical significance.

Conclusion

Bcl2 was identified in advanced prostate cancer and showed a trend toward greater expression in hormone-sensitive cancer. There was no correlation between Bcl2 and the clinical variables analyzed. However, there was a negative correlation between Bcl2 stain intensity and body weight and a positive trend between Bcl2 and disease duration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista mexicana de urologia
Revista mexicana de urologia Medicine-Urology
CiteScore
0.20
自引率
0.00%
发文量
49
期刊介绍: Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.
期刊最新文献
Fe de errores de «Resultados obtenidos con nefrolitotomía percutánea y su correlación con las escalas de Guy y S.T.O.N.E. en un hospital de la Ciudad de México» [Rev Mex Urol. 2016;76:331] Blindness due to a systemic fungal infection in a patient with a ureteral catheter Permixon® en el tratamiento de los síntomas del tracto urinario inferior por hiperplasia benigna de próstata: Nuevas aportaciones Resultados de la nefrectomía laparoscópica en pacientes obesos y no obesos Alfa-1 bloqueantes y resultados urodinámicos en varones con síntomas del tracto urinario inferior relacionados con obstrucción benigna de próstata: ¿fin de la controversia?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1